Compile Data Set for Download or QSAR
Report error Found 382 of affinity data for UniProtKB/TrEMBL: Q96RU2
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708839(US20240425513, Example 20)
Affinity DataIC50: 1nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM50618514(CHEMBL5401467)
Affinity DataIC50: 40nMAssay Description:Inhibition of USP28 (149 to 703 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ub-AMC as substrate by fluorescence based a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708840(US20240425513, Example 21)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708841(US20240425513, Example 22)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708843(US20240425513, Example 24)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708844(US20240425513, Example 25)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708845(US20240425513, Example 26)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708846(US20240425513, Example 27)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708847(US20240425513, Example 28)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708848(US20240425513, Example 29)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708851(US20240425513, Example 32)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708852(US20240425513, Example 33)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708853(US20240425513, Example 34)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708854(US20240425513, Example 35)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708855(US20240425513, Example 36)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708856(US20240425513, Example 37)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708857(US20240425513, Example 38)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708858(US20240425513, Example 39)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708859(US20240425513, Example 40)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708860(US20240425513, Example 41)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708862(US20240425513, Example 43)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708863(US20240425513, Example 44)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM50618513(CHEMBL5431014)
Affinity DataIC50: 100nMAssay Description:Inhibition of USP28 (149 to 703 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ub-AMC as substrate by fluorescence based a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM50618502(CHEMBL5398929)
Affinity DataIC50: 110nMAssay Description:Inhibition of USP28 (149 to 703 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ub-AMC as substrate by fluorescence based a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM50618512(CHEMBL5402874)
Affinity DataIC50: 150nMAssay Description:Inhibition of USP28 (149 to 703 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) using Ub-AMC as substrate by fluorescence based a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/14/2024
Entry Details
PubMed
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478023(US10889592, Compound I-3 | US11325917, Compound I-...)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478025(US10889592, Compound I-5 | US10889592, Compound I-...)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478026(US10889592, Compound I-6)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478027(US10889592, Compound I-7 | US11325917, Compound I-...)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478029(US10889592, Compound I-10)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478038(US10889592, Compound I-15)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM478041(US10889592, Compound I-20)
Affinity DataIC50: 200nMAssay Description:USP28: Each assay was performed in a final volume of 20 μL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Cor...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/9/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481935(US10913753, Compound I-2)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481937(US10913753, Compound I-4)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481939(US10913753, Compound I-6)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481941(US10913753, Compound I-8)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481945(US10913753, Compound I-12)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481946(US10913753, Compound I-13 | US20230365583, Compoun...)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481947(US10913753, Compound I-14)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481948(US10913753, Compound I-15 | US10913753, Compound I...)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481949(US10913753, Compound I-16)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481951(US10913753, Compound I-18)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481952(US10913753, Compound I-19)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481954(US10913753, Compound I-21)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481955(US10913753, Compound I-22)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481967(US10913753, Compound I-34)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481968(US10913753, Compound I-35)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481969(US10913753, Compound I-36)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481970(US10913753, Compound I-37)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM481974(US10913753, Compound I-41)
Affinity DataIC50: 200nMAssay Description:USP28: The assay was performed in a final volume of 20 uL in assay buffer containing 20 mM Tris-HCl (pH 8.0, (1M Tris-HCl, pH 8.0 solution; Corning 4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/30/2021
Entry Details
Go to US Patent

Displayed 1 to 50 (of 382 total ) | Next | Last >>
Jump to: